Oncology growth drives an otherwise lacklustre Japanese market
This article was originally published in Scrip
Executive Summary
Held back by the effects of the general reimbursement price cut in April 2010, Japan's total prescription drug market edged up by less than 2% in the year to 31 March, although the oncology sector again bucked the trend and posted solid growth.